- Nguyen KS, Neal JW. First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors. Biologics 2012;6: 337–345.
- Yap TA, Popat S. Toward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancer. Pharmgenomics Pers Med 2014;7: 285–295.
- Ding D, Yu Y, Li Z, Niu X, Lu S. The predictive role of pretreatment epidermal growth factor receptor T790M mutation on the progressionfree survival of tyrosine-kinase inhibitor-treated non–small cell lung cancer patients: a meta-analysis. Onco Targets Ther 2014;7: 387–393.
- Nguyen KS, Neal JW, Wakelee H. Review of the current targeted therapies for non-small-cell lung cancer. World J Clin Oncol 2014;5 (4): 576–587.
- Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Dřevínek P, Griese M, McKone EF, Wainwright CE, Konstan MW, Moss R, Ratjen F, Sermet-Gaudelus I, Rowe SM, Dong Q, Rodriguez S, Yen K, Ordoñez C, Elborn JS; VX08–770–102 Study Group. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011;365 (18): 1663–1672.
- Yosunkaya E, Karaca E, Basaran S, Seven M, Yüksel A. Marked improvement in Segawa syndrome after L-dopa and selegiline treatment. Pediatr Neurol 2010;42 (5): 348–350.
- Mahida S, Hogarth AJ, Cowan C, Tayebjee MH, Graham LN, Pepper CB. Genetics of congenital and drug-induced long QT syndromes: current evidence and future research perspectives. J Interv Card Electrophysiol 2013;37 (1): 9–19.
- Arking DE, Pulit SL, Crotti L, van der Harst P, Munroe PB, Koopmann TT, Sotoodehnia N, Rossin EJ, Morley M, Wang X, et al Genetic association study of QT interval highlights role for calcium signaling pathways in myocardial repolarization. Nat Genet 2014;46 (8): 826–836.
Baylor University Medical Center Proceedings
The peer-reviewed journal of Baylor Scott & White Health
Volume 28, 2015 - Issue 3